Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Predictive Oncology's TumorGensis sells media to research medical centers » 08:50
01/14/21
01/14
08:50
01/14/21
08:50
POAI

Predictive Oncology

$0.90 /

-0.0048 (-0.53%)

Predictive Oncology…

Predictive Oncology announced that its wholly owned subsidiary TumorGenesis, Inc. in the last quarter has sold media to two top research medical centers, one in New York City and the other in Boston, Massachusetts. Both the New York City and the Boston orders are repeat orders and are focused on culturing ovarian cancer cells with specific research goals. One additional order came from a private company doing research on ovarian cancer.

ShowHide Related Items >><<
POAI Predictive Oncology
$0.90 /

-0.0048 (-0.53%)

Hot Stocks
Predictive Oncology's Helomics completes integration of Quantitative Medicine » 08:51
01/06/21
01/06
08:51
01/06/21
08:51
POAI

Predictive Oncology

$0.84 /

+0.12 (+16.67%)

Predictive Oncology…

Predictive Oncology announced that its wholly owned subsidiary Helomics has completed the integration of Quantitative Medicine's novel active-learning Computational Research Engine with Helomics' proprietary TumorSpace knowledgebase of 150,000 tumor drug response profiles and the TruTumor patient primary tumor cell line assay. This integration allows Helomics to offer a revolutionary new AI-driven patient-centric drug discovery service to Pharmaceutical companies that will significantly improve the chances of successfully translating new drugs into the clinic.

ShowHide Related Items >><<
POAI Predictive Oncology
$0.84 /

+0.12 (+16.67%)

Hot Stocks
Predictive Oncology hires Landon Capital as IR firm » 08:40
01/05/21
01/05
08:40
01/05/21
08:40
POAI

Predictive Oncology

$0.72 /

+0.0024 (+0.33%)

Predictive Oncology…

Predictive Oncology announced that it has engaged Landon Capital to provide investor relations services effective December 30, 2020. Services will include introductions to investors, financial and industry analysts, registered brokers and financial writers with a view to informing such groups about developments in the Company's business and affairs. Landon Capital will assist to develop a database of individuals, financial institutions or other persons potentially interested in receiving publicly available information relating to the Company and making efforts to efficiently provide such information.

ShowHide Related Items >><<
POAI Predictive Oncology
$0.72 /

+0.0024 (+0.33%)

Over a month ago
Hot Stocks
Predictive Oncology urges shareholders to approve proposals at Special Meeting » 08:50
12/09/20
12/09
08:50
12/09/20
08:50
POAI

Predictive Oncology

$0.70 /

-0.0122 (-1.72%)

Predictive Oncology sent…

Predictive Oncology sent a letter to shareholders regarding its virtual Special Meeting of Stockholders, original scheduled for December 1, 2020, which will be reconvened December 30, 2020 at 3 p.m. CST. The Board of Directors and management of Predictive Oncology urge all shareholders to vote "FOR" the proposals being considered at the Special Meeting, primarily because the reincorporation in Nevada will eliminate the obligation to pay the injurious annual Delaware franchise tax, which is currently equal to approximately $170,000 per year. The company can save approximately $158,000 annually in state taxes by reincorporating in Nevada. The letter read, "Our Special Meeting of the Shareholders on December 1, 2020 was adjourned to December 30, 2020. We need your vote! We previously sent you proxy materials in connection with our Special Meeting of Shareholders, and according to our records, we have not yet received your vote. We are asking you to vote for allowing the Company to reincorporate in the state of Nevada, moving away from Delaware. Our Board believes that there are several reasons why a reincorporation in Nevada is in the best interests of the Company and our stockholders. First and foremost, the reincorporation in Nevada will eliminate our obligation to pay the injurious annual Delaware franchise tax, which is currently equal to approximately $170,000 per year. We can save approximately $158,000 annually in state taxes by reincorporating in Nevada. Also, we believe that for the reasons described in the proxy materials, in general, Nevada law provides greater protection to our directors, officers and the Company than Delaware law. Your vote is very important, regardless of the number of shares you own. The reincorporation, to be approved at the Special Meeting, must receive a "For" vote from a majority of the outstanding shares of common stock of the Company. At our recent Annual Meeting, the Reincorporation vote received far more "For" votes than "Against" votes, however, we did not reach the required number of total votes for a majority of the outstanding shares."

ShowHide Related Items >><<
POAI Predictive Oncology
$0.70 /

-0.0122 (-1.72%)

Hot Stocks
Predictive Oncology announces adjournment of special meeting » 08:04
12/02/20
12/02
08:04
12/02/20
08:04
POAI

Predictive Oncology

$0.73 /

+0.0311 (+4.42%)

Predictive Oncology…

Predictive Oncology announced that its virtual Special Meeting of Stockholders, scheduled for December 1, 2020, was convened and adjourned without any business being conducted due to the fact that quorum was not achieved. The Special Meeting will be reconvened December 30, 2020 at 3 p.m. CST.

ShowHide Related Items >><<
POAI Predictive Oncology
$0.73 /

+0.0311 (+4.42%)

Over a quarter ago
Hot Stocks
Predictive Oncology CEO says cash burn 'stable', 'trending downward' » 08:45
10/06/20
10/06
08:45
10/06/20
08:45
POAI

Predictive Oncology

$0.77 /

+0.0045 (+0.59%)

Predictive Oncology…

Predictive Oncology released a CEO letter to the shareholders, which read in part, " I know you have watched our stock price decline steadily over the past few weeks. I am writing to assure you that there is a lot of encouraging progress to report - in other words, our company is not in the condition that the stock price might indicate. I want to take this opportunity to review where Predictive Oncology stands as of today. Our cash burn is stable and trending downward. Our revenues are stable and trending upward. Our available cash is adequate for operations and we have the ability to utilize our equity line of credit, which has a remaining amount of over $10M. The best news is in the operational progress in our various divisions. Starting with Skyline Medical, this division is self-supporting from a cash standpoint. Sales of disposables used on previously sold machines more than cover the operating expenses of this division, and we continue to sell new machines on a regular basis, adding to future disposables revenues. Our Helomics division is coming along handsomely. We have launched a restructured clinical test offering to clinicians for ovarian cancer. The response from oncologists to this re-configured test has been excellent and we expect this effort, as well as our other tests, to be revenue generating by year end and should be able to cover the bulk of Helomics operating expenses going forward. We have made solid progress on the UPMC-Magee Women's Hospital project and are close to completing our AI-driven models of drug response and patient outcomes. We are also finishing the sequencing of the tumors from the patients involved and have completed the "reach back" for patient outcome data (i.e. including data on what happened to the patient). The Magee Study validates our ability to sequence our tumor inventory as well as to do the reach back for patient outcomes. The acquisition and integration of the newly acquired Quantitative Medicine AI software into Helomics' existing computer model is a major accomplishment. We have begun discussions with large Pharma companies in an effort to form major, multi-year, multi-target, milestone based strategic partnerships. We hope to make more announcements soon. Our TumorGenesis division has not been resting on its' laurels. We will be introducing our Ovarian Cell Line Media at the BIO-Europe Conference. This media will allow researchers to isolate and successfully culture ovarian cancer cells that have previously not been cultured. Under the NCI Prevent Cancer Program, TumorGenesis, Cornell Medical and Helomics will coordinate with and seek funding for this program to help identify the best culture media for the studying of mutations that increase the risk of ovarian and breast cancers as well as other types of cancers. TumorGenesis is registering with the U.S. government as a contractor for developmental work in cancer cell capture and screening of compounds for the prevention and treatment of cancer. TumorGenesis Discovery Kits will also launch at the BIO-Europe conference. These kits will allow researchers to study and tag target cancer cells as well as normal cells often associated with tumors and let pathologists screen approved drug therapies across isolated and properly identified ovarian cancer samples from patients. Last, but certainly not least, is Soluble Biotech. We have moved this division into a new Research Park located in Birmingham, Alabama. This new facility effectively quadruples our Soluble's office and research space. This state of the art company provides optimized FDA-approved formulations for vaccines, antibodies and other protein therapeutics in a faster and lower cost basis to its customers. In addition, the company recently purchased and installed a suite of new research equipment that enables protein degradation studies which is a new and substantial line of business for the company. Our investment in new equipment, combined with our proprietary existing equipment, expands the company's capabilities to include temperature-controlled humidity chamber analysis, temperature-controlled photo-stability analysis, differential scanning calorimetry, viscometry analysis, UV/Vis spectroscopy analysis, High Performance Liquid Chromatography, a state-of-the-art automated dynamic laser light scattering system (DLS), free flow particle microscopic analysis, circular dichroism analysis, electron microscopy and high resolution mass spectrometry. Soluble Biotech is also planning to begin the development of an FDA-approved GMP facility to further support pharmaceutical needs. We have already secured a sizable contract and we are bidding on several more. I expect Soluble Biotech to be generating revenues by the end of the year."

ShowHide Related Items >><<
POAI Predictive Oncology
$0.77 /

+0.0045 (+0.59%)

Hot Stocks
Soluble Biotech receives first contract with major pharmaceutical company » 08:35
08/20/20
08/20
08:35
08/20/20
08:35
POAI

Predictive Oncology

$1.17 /

-0.06 (-4.88%)

Predictive Oncology…

Predictive Oncology announced that its Soluble Biotech division, a provider of soluble and stable formulations for proteins, just received its first substantial contract from a major pharmaceutical company since being acquired by Predictive Oncology in May 2020. The project involves protein expression followed by solubility studies, areas of significant expertise within Soluble Biotech.

ShowHide Related Items >><<
POAI Predictive Oncology
$1.17 /

-0.06 (-4.88%)

POAI Predictive Oncology
$1.17 /

-0.06 (-4.88%)

Hot Stocks
Predictive Oncology's Skyline Medical sells 8 STREAMWAY Systems » 08:33
08/18/20
08/18
08:33
08/18/20
08:33
POAI

Predictive Oncology

$1.30 /

-0.04 (-2.99%)

Predictive Oncology…

Predictive Oncology announced that its Skyline Medical division has completed the sale of 8 STREAMWAY systems to a large university hospital organization in Virginia for a new surgical center. The hospital system already has 2 STREAMWAY systems currently in use. The sale is expected to generate approximately 4,000 procedures annually. The company has now sold 13 STREAMWAY systems during Q3 2020.

ShowHide Related Items >><<
POAI Predictive Oncology
$1.30 /

-0.04 (-2.99%)

POAI Predictive Oncology
$1.30 /

-0.04 (-2.99%)

Hot Stocks
Predictive Oncology urges shareholders to approve compensation-related proposals » 08:57
08/11/20
08/11
08:57
08/11/20
08:57
POAI

Predictive Oncology

$1.70 /

-0.02 (-1.16%)

Predictive Oncology…

Predictive Oncology issued a letter to shareholders discussing the Company's recent accomplishments and voting recommendations from its Board of Directors for two proposals that are scheduled for shareholder vote on September 3, 2020. The company said, "Predictive Oncology is committed to executing our strategic vision to develop and commercialize an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value for our shareholders. Over the last six months we have been diligently assembling a portfolio of assets and aligning our capital and governance structures to help us achieve this vision. At our annual meeting on September 3, 2020, we are asking you to approve two important compensation-related proposals - repricing stock options for executives and key employees, and an increased share reserve for the stock incentive plan. Management and the Board considered these proposals carefully before recommending them for your approval, and we need your vote FOR these proposals. Approval is critical as we expand upon our considerable recent business accomplishments and enhance shareholder value by attracting and retaining talented management...At our Annual Meeting on September 3, 2020 you are being asked to approve a number of proposals that are described in our proxy statement that we filed with the Securities and Exchange Commission on July 29, 2020 and have mailed to our stockholders. Two of the proposals are vital to retaining and attracting top talent aligned with executing our corporate strategy such that we can scale and grow our business and achieve profitability...The Board has determined that adverse changes in the market price of the Company's common stock since the Eligible Options were granted could materially interfere with the Company's efforts to retain the service of its existing officers and employees. In Proposal No. 3, Predictive is seeking approval of a one-time repricing of all stock options outstanding under the Company's Amended and Restated 2012 Stock Incentive Plan held by current officers or employees of the Company which have an exercise price higher than $1.54 per share, but excluding stock options granted for service on the Board of Directors. More specifically, the proposal requests stockholder approval to change the exercise price of eligible options to $1.54 per share, equal to the closing sale price of the common stock on July 1, 2020, the day before the Board approved the repricing. The Board recommends the option repricing to encourage an increasing alignment of their interests with those of the Company's stockholders and their stake in the long-term performance and success of the Company. When the market price for the Company's common stock is significantly below the applicable exercise price of an option, for example, the Board believes that the option holder is not likely to exercise that option and will not have the desired incentive that the option was intended to provide....Proposal No. 4: Increase in Reserve in Stock Incentive Plan. The Company does not possess enough options in its stock incentive option plan to incentivize valued employees currently working hard to bring success to Predictive and align their incentives with our shareholders. It is also critical to have a large enough share reserve under the plan to attract prospective employees to our organization. In order to meet its business and growth objectives, the company will need to hire talented additional management and operating personnel. In Proposal No. 4, Predictive is requesting stockholder approval to increase the share reserve by 750,000 shares, to a total of 1,750,000 shares. Currently, options to purchase 830,488 shares of common stock are subject to outstanding stock options under the Restated Plan. In determining the amount of the increase in the Restated Plan, the Predictive Board carefully considered its intention to grant further equity awards to current and future executive officers and key employees and directors. The Restated Plan also eliminates certain limitations on individual awards that are no longer required under applicable tax laws. The Board believes that approval of Proposal No. 4 is in the best interests of Predictive and its stockholders because the availability of an adequate number of shares reserved for issuance is important in attracting, retaining and motivating employees, consultants and directors in order to achieve the company's long-term growth and profitability objectives."

ShowHide Related Items >><<
POAI Predictive Oncology
$1.70 /

-0.02 (-1.16%)

POAI Predictive Oncology
$1.70 /

-0.02 (-1.16%)

Hot Stocks
Predictive Oncology appoints three directors to board » 08:45
07/14/20
07/14
08:45
07/14/20
08:45
POAI

Predictive Oncology

$1.44 /

-0.02 (-1.37%)

Predictive Oncology…

Predictive Oncology announced the appointment of three new members to the company's board of directors, effective immediately. Joining the board are: Dr. Nancy Chung-Welch, Ph.D.; Mr. Charles L. Nuzum, CPA; Mr. Greg St. Clair. Predictive Oncology's board is comprised of seven members. Each of the new board members will serve as independent directors as defined by Nasdaq Corporate Governance rules. Dr. Chung-Welch currently serves as an independent consultant advising life science companies and institutional investors with an emphasis on the research product/tools market. Mr. Nuzum currently provides project-based financial consulting services to companies such as McKesson, BioMarin, AutoDesk and Squire Patton Boggs and mentors start-up companies. Mr. St. Clair is Founder and a Managing Member of SunStone Consulting.

ShowHide Related Items >><<
POAI Predictive Oncology
$1.44 /

-0.02 (-1.37%)

POAI Predictive Oncology
$1.44 /

-0.02 (-1.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.